Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by pabalooon Jun 01, 2020 9:40pm

62 Views

Post# 31099305

RE:RE:RE:RE:No Trulance revenues (yet)

Totally agree. There should be No reason a judge would arbitrate an end to a contractual agreement unless the party was egregious and unfulfilled there committed obligations. Bausch appears to be sour about not holding Canadian rights to Trulance and dearly wants them back. I'm guessing after ruling Bausch will try to acquire the rights. Cipher is in a premium spot and the ball will clearly be in there court to do what they want with this block buster drug. Hoping for a buy out of Trulance in the 20 million range, .80 cents a share seems fair.

Bullboard Posts

E3 inches closer to Alberta's first lithium production plant